Madrigal Pharmaceuticals (MDGL) Cash & Current Investments (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash & Current Investments data on file, last reported at $232.2 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 72.45% year-over-year to $232.2 million in Q1 2026; TTM through Mar 2026 was $232.2 million, a 72.45% decrease from a year earlier, with the FY2025 full-year figure at $983.6 million, up 836.55% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $232.2 million, down from $983.6 million in the prior quarter.
• Over the last five years, Cash & Current Investments for MDGL reached as high as $1.1 billion in Q3 2025 and fell as low as $105.0 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $566.1 million across 5 years, with a median of $358.8 million in 2022.
• Across the five-year window, Cash & Current Investments tumbled 83.44% in 2024 and soared 836.55% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $358.8 million in 2022, then jumped by 76.75% to $634.1 million in 2023, then tumbled by 83.44% to $105.0 million in 2024, then surged by 836.55% to $983.6 million in 2025, then slumped by 76.39% to $232.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $232.2 million in Q1 2026, $983.6 million in Q4 2025, and $1.1 billion in Q3 2025.